Short-Term Rationing of Combination Antiretroviral Therapy: Impact on Morbidity, Mortality, and Loss to Follow-Up in a Large HIV Treatment Program in Western Kenya

Table 2

Cox proportional (unadjusted and adjusted) hazard ratios for predictors of cart initiation.

Covariate	Univariate analysis			Multivariate analysis^b
	Unadjusted hazard ratio	95% confidence interval (CI)	𝑃 value	Adjusted hazard ratio (AHR)	95% Confidence interval (CI)	𝑃 value
Enrolled in the cap period	0.86	0.82, 0.90	<0.001	0.87	0.83, 0.92	<0.001
Use of Cotrimoxazole or Dapsone^a	3.22	2.98, 3.48	<0.001	2.08	1.89, 2.29	<0.001
On TB treatment^a	0.77	0.73, 0.82	<0.001	0.60	0.56, 0.64	<0.001
Male gender	1.13	1.08, 1.19	<0.001	1.14	1.09, 1.21	<0.001
Age (per year increase)^a	1.00	1.00, 1.00	0.100	1.00	1.00, 1.00	0.950
CD4 (per cell increase)^a	0.995	0.994, 0.995	<0.001	0.995	0.995, 0.996	<0.001
WHO Stage I^a	1.00			1.00
WHO Stage II^a	1.16	1.07, 1.26	<0.001	1.08	1.00, 1.17	0.053
WHO Stage III^a	0.89	0.83, 0.95	0.001	1.20	1.11, 1.29	<0.001
WHO Stage IV^a	1.33	1.20, 1.46	<0.001	1.86	1.67, 2.07	<0.001
Urban Clinic^a	1.03	0.99, 1.09	0.162	1.06	1.01, 1.11	0.030
Travel time < 30 min	1.00			1.00
Travel time 30–60 min	1.02	0.96, 1.09	0.494	0.99	0.93, 1.06	0.749
Travel time 1-2 hr	1.05	0.98, 1.12	0.151	0.99	0.92, 1.06	0.742
Travel time > 2 hr	1.11	1.03, 1.20	0.008	1.05	0.97, 1.14	0.246

^aAt Enrollment.
^bAdjusted for all covariates.